Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (461-470 of 649) with videos related to

Pageof 65
Sort By:
Wiener Medizinische Wochenschrift (1946)|October 17, 2015
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementEdgar Petru, Christian F Singer, Stephan Polterauer, et al.
Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
Clinical Genetics|December 6, 2017
The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancerK A Metcalfe, J Lubinski, J Gronwald, et al.
BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2011
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumabM Bates, J Sperinde, W J Köstler, et al.
Oncotarget|January 14, 2017
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cellsRenate Wagner, Gerald Stübiger, Daniel Veigel, et al.
Bone|May 13, 1999
Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging studyH Buckler, W Fraser, D Hosking, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
British Journal of Cancer|March 2, 2025
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancerAriane Steindl, Clara Zach, Luzia Berchtold, et al.
Endocrine-Related Cancer|November 30, 2007
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutationsG Hudelist, T Wagner, M Rosner, et al.
Pageof 65

Showing results (461-470 of 649) with videos related to

Sort By:
Pageof 65
Wiener Medizinische Wochenschrift (1946)|October 17, 2015
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementEdgar Petru, Christian F Singer, Stephan Polterauer, et al.
Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
Clinical Genetics|December 6, 2017
The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancerK A Metcalfe, J Lubinski, J Gronwald, et al.
BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2011
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumabM Bates, J Sperinde, W J Köstler, et al.
Oncotarget|January 14, 2017
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cellsRenate Wagner, Gerald Stübiger, Daniel Veigel, et al.
Bone|May 13, 1999
Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging studyH Buckler, W Fraser, D Hosking, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
British Journal of Cancer|March 2, 2025
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancerAriane Steindl, Clara Zach, Luzia Berchtold, et al.
Endocrine-Related Cancer|November 30, 2007
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutationsG Hudelist, T Wagner, M Rosner, et al.
Pageof 65